$TVTX News

Travere Therapeutics to Report Third Quarter 2026 Financial Results

Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA Nephropathy

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics (TVTX) Is Down 6.7% After New FILSPARI Data And Patent Extension - What's Changed

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Travere Therapeutics (TVTX) Sets CEO Handover For December 2026

Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today

Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

Travere Therapeutics Appoints Bradley L. Campbell President, CEO, Effective Dec. 1, Succeeding Eric Dube

Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics' Outlook Brightens As Turnaround Looms

IBD Stock Of The Day, Travere Therapeutics, Tests Another Breakout. Can The Stock Get Any 'Sweeter?'

Travere Therapeutics: Valuation Suggests A Buy

Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline